^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Noxafil (posaconazole)

    i
    Other names: MK-5592, SCH 56592
    Associations

    News

    Trials
    Company:
    Ligand, Merck (MSD)
    Drug class:
    Cytochrome P450 inhibitor
    Related drugs:
    Associations

    News

    Trials
    14d
    Simultaneous Determination of Venetoclax and Posaconazole in Human Plasma by UPLC-MS/MS: Application to Therapeutic Drug Monitoring in Acute Myeloid Leukemia Patients. (PubMed, Drug Des Devel Ther)
    The trough concentrations of venetoclax were 9326.88 ± 12,169.05 ng/mL in patients treated with venetoclax alone, and 31,623.55 ± 28,453.67 ng/mL in patients treated with venetoclax in combination with posaconazole. A rapid and simple method was established and successfully applied to the simultaneous determination of the concentrations of venetoclax and posaconazole in AML patients, providing a basis for TDM and clinical pharmacokinetic analysis of these drugs in AML patients.
    Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Venclexta (venetoclax) • Noxafil (posaconazole)
    16d
    ReSPECT: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (clinicaltrials.gov)
    P3, N=602, Completed, Mundipharma Research Limited | Active, not recruiting --> Completed
    Trial completion
    |
    Chr del(5q)
    |
    Noxafil (posaconazole)
    27d
    ReSPECT: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (clinicaltrials.gov)
    P3, N=602, Active, not recruiting, Mundipharma Research Limited | Completed --> Active, not recruiting
    Enrollment closed
    |
    Chr del(5q)
    |
    Noxafil (posaconazole)
    1m
    Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=72, Recruiting, Shandong Cancer Hospital and Institute | N=20 --> 72
    Enrollment change
    |
    Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Noxafil (posaconazole)
    2ms
    Posaconazole attenuates arsenic trioxide toxicity and enhances safety and efficacy while reducing invasion and metastasis in non-small-cell lung cancer. (PubMed, Pulm Pharmacol Ther)
    Furthermore, flow cytometry and colony formation assays revealed that PCZ attenuates and reduces the apoptotic/necrotic effects of ATO. In conclusion, PCZ synergistically and effectively reduces the adverse cytotoxic effects of ATO in lung cancer cells, providing a promising new therapeutic strategy for lung cancer treatment.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • GLI1 (GLI Family Zinc Finger 1) • HMGA2 (High mobility group AT-hook 2) • MMP9 (Matrix metallopeptidase 9)
    |
    arsenic trioxide • Noxafil (posaconazole)
    2ms
    Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients (clinicaltrials.gov)
    P=N/A, N=360, Completed, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Completed
    Trial completion
    |
    Noxafil (posaconazole)
    2ms
    ReSPECT: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (clinicaltrials.gov)
    P3, N=602, Active, not recruiting, Mundipharma Research Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Chr del(5q)
    |
    Noxafil (posaconazole)
    2ms
    A Retrospective Study on the Correlation between Posaconazole Concentration and the Incidence of Clinical Adverse Reactions (ChiCTR2500114180)
    P=N/A, N=200, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital
    New trial
    |
    Noxafil (posaconazole)
    2ms
    A multicenter, randomized controlled phase II clinical study of oral posaconazole combined with chemotherapy and PD-1 inhibitors as neoadjuvant treatment for early or locally advanced triple-negative breast cancer (ChiCTR2500098742)
    P=N/A, N=40, Recruiting, Cancer Hospital of Shandong First Medical University (Shandong Cancer institute, Shandong Cancer Hospital); Cancer Hospital of Shandong First Medical | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Noxafil (posaconazole)
    2ms
    MOMENTUM: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (clinicaltrials.gov)
    P1/2, N=84, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    Noxafil (posaconazole)
    2ms
    Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (clinicaltrials.gov)
    P2, N=10, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    Imbruvica (ibrutinib) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Noxafil (posaconazole)
    3ms
    A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers. (PubMed, Clin Pharmacol Drug Dev)
    Co-administration with posaconazole increased SGR-1505 exposure 3-fold...Asymptomatic, reversible indirect hyperbilirubinemia occurred, consistent with inhibition of UGT1A1. SGR-1505 was well-tolerated and exhibited favorable pharmacokinetic and pharmacodynamic properties, supporting further clinical development.
    P1 data • PK/PD data • Journal
    |
    IL2 (Interleukin 2) • MALT1 (MALT1 Paracaspase)
    |
    Noxafil (posaconazole) • SGR-1505